Pfizer Stock Surges Nearly 14% in August Due to Strong Earnings and Regulatory Advances
In a surprising turn for investors, Pfizer (NYSE: PFE) stock rose nearly 14% in August after outperforming its pharmaceutical peers. This was driven by better-than-expected second-quarter earnings on Aug. 4, with revenue reaching $15 billion—up from the expected $14.4 billion—and adjusted EPS of $0.77 per share versus an estimate of $0.68. The company also raised its full-year revenue guidance to between $60.5 billion and $62.5 billion. Pfizer's top-selling drug, Eliquis, contributed significantly with 19% year-over-year sales growth. However, the looming patent expiration for Eliquis poses a future challenge. In August, Pfizer also achieved regulatory milestones: the European Medicines Agency validated its application for PF-07307405—a next-gen Lyme disease treatment—and the FDA approved an updated version of its Comirnaty vaccine developed with BioNTech. Analysts suggest that while investors may be underestimating Pfizer due to a lack of recent blockbuster drugs, the company's strong pipeline and strategic acquisitions position it for long-term growth. Despite these positives, some analysts have not included Pfizer in their top stock picks.
